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Background: Rituximab is a B cell depleting anti-CD20 monoclonal antibody. CD20 is not expressed on mature
plasma cells and accordingly rituximab does not have immediate effects on immunoglobulin levels. However, after
rituximab some patients develop hypogammaglobulinaemia.
Methods: We performed a single centre retrospective review of 177 patients with multisystem autoimmune
disease receiving rituximab between 2002 and 2010. The incidence, severity and complications of
hypogammaglobulinaemia were investigated.
Results: Median rituximab dose was 6 g (1–20.2) and total follow-up was 8012 patient-months. At first rituximab,
the proportion of patients with IgG <6 g/L was 13% and remained stable at 17% at 24 months and 14% at
60 months. Following rituximab, 61/177 patients (34%) had IgG <6 g/L for at least three consecutive months, of
whom 7/177 (4%) had IgG <3 g/L. Low immunoglobulin levels were associated with higher glucocorticoid doses
during follow up and there was a trend for median IgG levels to fall after ≥ 6 g rituximab. 45/115 (39%) with
IgG ≥6 g/L versus 26/62 (42%) with IgG <6 g/L experienced severe infections (p = 0.750). 6/177 patients (3%)
received intravenous immunoglobulin replacement therapy, all with IgG <5 g/L and recurrent infection.
Conclusions: In multi-system autoimmune disease, prior cyclophosphamide exposure and glucocorticoid therapy
but not cumulative rituximab dose was associated with an increased incidence of hypogammaglobulinaemia.
Severe infections were common but were not associated with immunoglobulin levels. Repeat dose rituximab
therapy appears safe with judicious monitoring.
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Infection, AutoimmuneBackground
Rituximab is increasingly used for multi-system auto-
immune diseases, such as primary systemic vasculitis and
systemic lupus erythematosus (SLE) [1-9]. Rituximab was
licensed for the treatment of B cell lymphoma in 1997
[10], rheumatoid arthritis (RA) in 2006 [11-13] and ANCA
associated vasculitis (AAV) in 2011.
Rituximab is a chimeric murine/human monoclonal
antibody that results in complete peripheral blood B cell* Correspondence: ronasmith@doctors.net.uk
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unless otherwise stated.depletion for variable time periods; typically 6–12
months. During B cell depletion, new vaccine responses
are impaired and a theoretical risk of new infections
exists [14]. However, since CD20 is highly expressed on
B cells but not on stem cells or mature plasma cells, B
cell regeneration from precursors is not directly com-
promised by rituximab and in the short term established
humoral immunity is preserved; usually with stable levels
of total IgG and established vaccination antibodies [14].
However, when rituximab is used in cohorts with high
prior immunosuppressive exposure, where stem cell and
plasma cell compartments maybe compromised, or when
rituximab is administered long term using repeat dosingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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existing humoral immunity maybe impaired. Hypogam-
maglobulinaemia has occurred in more than 50% of
non-Hodgkin’s lymphoma (NHL) patients, especially in
those receiving rituximab in combination with chemo-
therapy or bone marrow transplantation [15-18], and
less so in RA patients treated with rituximab where
3.5% had IgG levels below the normal range [19]. Hypo-
gammaglobulinaemia has also been reported in small
cohorts with primary systemic vasculitis treated with
rituximab [20-23], although the impact of prior high im-
munosuppression exposure, and repeat rituximab dosing,
as is widely used in clinical practice, are unclear.
Immunoglobulin plays a major role in adaptive immun-
ity, and severe depletion of immunoglobulin, as observed
in primary immunodeficiency syndromes increases infec-
tion risk [24]. The potential development of secondary
immunodeficiency due to immunosuppressive medication,
including the impact of prolonged B cell depletion on IgG
levels and infection risk, is not well studied in patients
with autoimmune disease.
We report on the frequency and severity of hypogam-
maglobulinaemia, and associated infection rates in a large
cohort of rituximab treated patients with severe multi-
system autoimmune diseases and prolonged follow-up.
Methods
This was a retrospective study conducted at Addenbrooke’s
Hospital, Cambridge, UK, which serves as a tertiary referral
clinic and follows approximately 1000 patients with pri-
mary systemic vasculitis and SLE. In accordance with
UK National Health Service Research Ethics Committee
guidelines, ethical approval and patient consent were
not required for this work because it comprises retro-
spective data and all treatment decisions were made
prior to our evaluation.
All patients with multi-system autoimmune disease
treated with rituximab between 2002 and 2010 were stud-
ied. 104 cases have previously been reported [3,5,25-27]
and seven enrolled in a randomized controlled trial of
rituximab [1] are also included in this cohort. Patients
were excluded if they had fewer than six months follow-
up or required repeated plasma exchange (PLEX).
Clinical and laboratory assessments
The data was collected retrospectively from patient
notes and clinical databases. Data collection included
pre-rituximab demographics, disease activity assessments,
medications, adverse events and immunoglobulin levels at
each clinical assessment.
Dose of rituximab
Rituximab induction therapy consisted of either 1000 mg
repeated after two weeks or 375 mg/m2/week × 4. Patientsreceived further rituximab at the time of relapse or at 6
monthly intervals as a remission maintenance therapy.
Disease activity
AAV disease activity was graded by the Disease Extent
Index (DEI score) [28] and by investigators’ assessment
of disease activity as either full remission (DEI ≤2 and a
steroid dose ≤10 mg daily), partial remission (greater
than 50% reduction in DEI), ongoing disease/progressive
disease (treatment failure), or relapse (increase in disease
activity necessitating additional therapy beyond a tempor-
ary increase in glucocorticoid therapy).
SLE disease activity was graded by the BILAG disease
activity (British Isles Lupus Assessment Group) and by
investigators’ assessment of disease activity as either full
remission (absence of BILAG A, B and C), partial re-
mission (absence of BILAG A and B), ongoing disease/
progressive disease (treatment failure), or relapse (in-
crease in disease activity which required an increase in
immunosuppressive therapy).
Immunoglobulin levels
IgG hypogammaglobulinaemia was defined by serum
IgG <6 g/L (normal range 6.0-13.0 g/l) for at least three
consecutive months at any point during follow-up, and
classified as mild (5–5.9 g/L), moderate (3–4.9 g/L) and
severe (<3 g/L). IgM and IgA hypogammaglobulinaemia
were defined by serum IgM levels <0.4 g/L (normal
range 0.4-2.2 g/l) and IgA levels <0.8 g/L (normal range
0.8-3.7 g/l).
Infections
Infection was defined as severe when requiring hospital-
isation and/or intravenous (IV) antibiotics.
Statistical analysis
Statistical analysis was performed using SPSS version 15
and GraphPad Prism version 5.01 (GraphPad Software,
San Diego, CA). Results are expressed as values and pro-
portions for categorical variables and medians and ranges
for continuous variables. Clinical assessments and labora-
tory data were collected on a monthly basis. For missing
values (e.g. if a patient did not attend clinic that month) a
last value carried forward method was used until end of
individual patient follow-up. The median interval between
assessments was 3 months, with a median of 14 assess-
ments per patient (1–55) and total patient follow-up of
8012 months. Changes in immunoglobulin levels over
time were compared by a Wilcoxon signed rank test and
between 2 groups by a Mann–Whitney U test. Propor-
tions of patients were compared using Fisher’s exact test
or Chi-squared test. Correlations were assessed using
Spearman’s rank correlation coefficient. Time to first se-
vere infection was analysed using Kaplan-Meier survival
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wise p value <0.05 was considered significant for all statis-
tical tests with appropriate adjustments being made for
the multiple testing of serial data.
Results
Patient characteristics
One hundred and ninety-one patients received rituximab
between 2002 and 2010. Fourteen were excluded; 10 due
to less than six months follow-up and four due to re-
peated plasma exchange (PLEX). One hundred and
seventy-seven patients were included (Table 1). The me-
dian age at first rituximab was 47 years (13–82); 31%
were male, and the majority had primary systemic vascu-
litis (56%). Median disease duration before rituximab
was 52 months (0–396) including 96% with relapsing/re-
fractory disease. The median number of prior immuno-
suppressive or immunomodulatory agents excluding
glucocorticoids was three (0–14) including prior cyclo-
phosphamide in 121/176 (69%) with a median cumula-
tive dose of 8 g (0–163). At time of first rituximab 72%
had active disease and 28% received rituximab for per-
sistent low grade disease activity or as remission main-
tenance therapy when other drugs were contraindicated.
Median follow up was 43 months (2–100). All patients
had at least six months of follow-up, except for four
who died within six months and were included in the
analysis.
118/177 patients (67%) received 2 × 1000 mg doses of
rituximab two weeks apart and 54/177 (31%), 375 mg/
m2/week × 4. Five did not complete the induction
course. 152/177 (86%) received further rituximab either
for treatment of relapse or for remission maintenance.
Median rituximab exposure was 6 g (1–20.2). Exposure
adjusted for body surface area (BSA) was 3.3 g/m2 (0.8-
10.4), and BSA adjusted exposure/year was 1.1 g/m2/year
(0.1-3.2) (for the 149 patients with BSA data available).
The adjustment for BSA and time was necessary as 63/
177 (36%) patients received one or more BSA adjusted
doses (375 mg/m2/week × 4) and follow-up duration
was variable.
At time of first rituximab, 102/177 patients (58%) were
receiving other agents; 42/177 (24%) cyclophosphamide,
28/177 (16%) mycophenolate mofetil, 10/177 (6%) hy-
droxychloroquine, 8/177 (5%) azathioprine, 8/177 (5%)
methotrexate and 9/177 (5%) other agents. Of the 42
who received previous cyclophosphamide; 7/42 (17%)
were enrolled in a randomized controlled trial (RITUX-
VAS) [1] and received two doses of cyclophosphamide in
accordance with the trial protocol.
Disease response
Rituximab was an effective therapy, with 151/171 patients
(88%) achieving complete or partial remission by sixmonths. Complete remission was seen in 117/171 (68%)
and partial remission in 34/171 (20%). 20/171 (12%) were
considered treatment failures. There was no relationship
between overall response (either complete or partial re-
mission) and the presence or absence of hypogammaglo-
bulinaemia (IgG < 6 g/l). In addition, no relationship was
identified when complete and partial remission were con-
sidered independently, or when hypogammaglobulinaemia
was sub-divided into moderate-severe (IgG < 5 g/l) or mild
(IgG 5–6 g/l).
Immunoglobulin
Frequency and severity of low immunoglobulin levels
Immunoglobulin data was available for 136/177 patients
(77%) at time of first rituximab treatment. 18/136 (13%)
had IgG hypogammaglobulinaemia (5% mild, 6% moder-
ate and 2% severe). Of the 18 that initially had IgG hypo-
gammaglobulinaemia, this was exacerbated in 13/18
(72%) following rituximab therapy. One experienced >50%
decrease in IgG level; 6 patients >25% decrease and 4
patients >10% decrease in IgG levels. At first rituximab,
14/136 (10%) had IgM hypogammaglobulinaemia and
14/136 (10%) had IgA hypogammaglobulinaemia (Table 2).
Of the 118 patients who had IgG >6 g/l at time of first
rituximab treatment, 27/118 (23%) subsequently went
on to develop IgG hypogammaglobulinaemia, persisting
for at least 3 consecutive months.
Following rituximab, 61/177 patients (34%) had IgG
hypogammaglobulinaemia, for at least three consecutive
months at some point during follow-up. Of these, 18/177
(10%) were mild, 36/177 (20%) moderate and 7/177
(4%) severe. After rituximab 90/177 patients (51%) had
IgM <0.4 g/L and 40/177 (23%) had IgA <0.8 g/L
(Table 2). During follow-up, the proportion of patients
with IgG hypogammaglobulinaemia remained stable;
13% at time of first rituximab, 17% at 24 months and
14% at 60 months. Excluding those patients with hypo-
gammaglobulinaemia at time of first rituximab, the
median time to develop hypogammaglobulinaemia was
18 months (1–65), and median time to the hypogam-
maglobulinaemia category of maximum severity was
35 months (1–70).
Median immunoglobulin levels
Overall, median IgG levels remained relatively stable
during follow-up, measuring at 9.3 g/L at time of first
rituximab, 8.4 g/L at six months (p = 0.388) and 8.25 g/L
at 60 months (N = 52) (p = 0.140). IgM levels fell from
0.8 g/L at time of first rituximab to 0.6 g/L at six months
(p < 0.001) and 0.55 g/L at 60 months (p < 0.001). Base-
line IgA levels were 1.9 g/L, 1.6 g/L at six months (p =
0.114) and 1.55 g/L at 60 months (p = 0.360) (Figure 1A).
For those with IgG <6 g/L (N = 18) at baseline, there
was a trend for levels to increase, from a median of
Table 1 Characteristics and treatments of patients
receiving rituximab
Baseline Characteristics (N = 177)
Age (years) at first rituximab 47 (13–82)
Male sex 54 (31%)
Diagnosis 100 (56%)
Primary Systemic Vasculitis 75 (42%)
Granulomatosis with polyangiitis (Wegener’s) 15 (8%)
Microscopic Polyangiitis 10 (6%)
Churg Strauss Syndrome 43 (24%)
Systemic lupus erythematosus 3 (2%)
Behcet’s disease 3 (2%)
Henoch Schonlein Purpura 28 (16%)
Other#
Prior disease duration (months) 52 (0–396)
Prior cyclophosphamide (N = 176) 121 (69%)
Cumulative cyclophosphamide (g) (N = 171) 8 (0–163)
Prior therapies (N = 176)
Mycophenolate Mofetil 123 (70%)
Azathioprine 107 (61%)
Methotrexate 46 (26%)
Intravenous immunoglobulin 40 (23%)
Hydroxychloroquine 29 (16%)
Anti-tumor necrosis factors agents 26 (15%)
Plasma exchange 26 (15%)
Alemtuzumab 20 (11%)
Other IS/IM$ 63 (36%)
Number of prior IS/IM agents (excluding steroids)
(N = 176)
3 (0–14)
Patient characteristics at first rituximab infusion
Indication
Active disease 127 (72%)
Consolidation of remission 50 (28%)
Relapsing/refractory disease 170 (96%)
New disease 7 (4%)
Follow-up (months) 43 (2–100)
Cyclophosphamide at time of rituximab 42 (24%)
Rituximab total dose
Total dose (g) (N = 177) 6 (1–20.2)
Dose/BSA (g/m2) (N = 149) 3.3 (0.8-10.4)
Dose/BSA/year (g/m2/year) (N = 149) 1.1 (0.1-3.2)
Data are presented for 177 patients, unless otherwise stated. Results are
expressed as either medians and ranges or numbers and proportions. All
values reported at/from the time of first ever rituximab.
#other diagnoses include neurological autoimmune disease (N = 7),
cryoglobulinaemia (N = 3), urticarial vasculitis (N = 3), polyarteritis nodosa
(N = 2), polychondritis (N = 2), polymyositis (N = 2), Takayasu’s disease (N = 1),
membranous nephropathy (N = 1), bullous pemphigoid (N = 1) and unclassified
autoimmune disease (N = 6).
$other IS/IM (immunosuppressant/immunomodulatory) agents include:
ciclosporin (N = 15), gusperimus (N = 13), tacrolimus (N = 10), dapsone (N = 4),
leflunomide (N = 4), sirolimus (N = 3), antithymocyte globulin (N = 2), colchicine
(N = 2), gold (N = 2), abatacept (N = 1), mefloquine (N = 1), other (N = 6).
BSA – body surface area.
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(p = 0.276) and 6.4 g/L at 60 months (N = 7) (p = 0.099)
(Figure 1B).
Effect of prior cyclophosphamide treatment on IgG levels
121/176 patients (69%) received prior cyclophosphamide
treatment. 46/121 (38%) who received prior cyclophospha-
mide and 16/55 (29%) who did not, developed IgG hypo-
gammaglobulinaemia (p = 0.308). In patients who received
prior cyclophosphamide median IgG levels were lower at
time of first rituximab (8.85 g/L vs. 10.4 g/L) (p = 0.025) but
not at 60 months (7.9 g/L vs. 9.7 g/L) (p = 0.138) (N = 51).
Effect of dose of rituximab on IgG levels
39/79 (49%) who received <6 g rituximab and 32/98
(33%) who received ≥6 g rituximab developed IgG hypo-
gammaglobulinaemia for at least 3 months (p = 0.527).
Patients who received <6 g of rituximab had stable IgG
levels during follow-up with a median of 8.5 g/L at time
of first rituximab, 8.1 g/L at six months (p = 0.204) and
8.7 g/L at 60 months (N = 21) (p = 0.178). In patients
who received ≥6 g rituximab, IgG levels trended down-
ward from a median of 9.8 g/L at time of first rituximab
to 9.3 g/L at six months (p = 0.989) and to 7.5 g/L at
60 months (N = 31) (p = 0.381) (Figure 1C).
Effect of glucocorticoid exposure on IgG levels
Median cumulative oral prednisolone exposure following
the first rituximab infusion was 7.25 g (0–54.5). There
was a negative correlation (r = −0.17 (CI −0.31 to −0.02)
p = 0.02) between total oral prednisolone exposure after
initial rituximab and IgG levels. Data on cumulative
glucocorticoid exposure prior to rituximab therapy was
unavailable. 57/177 (32%) received at least one dose of
intravenous methylprednisolone following rituximab. Of
those that received intravenous methylprednisolone 49%
(28/57) developed hypogammaglobulinaemia compared
to 28% (34/120) of those that did not (p = 0.011).
Effect of disease diagnosis on IgG levels
56% of patients in this cohort had primary systemic vas-
culitis; 24% SLE and 20% other autoimmune conditions.
There was no association between diagnosis and the devel-
opment of IgG hypogammaglobulinaemia (Chi-square =
3.24; df = 2; p = 0.198).
Severe hypogammaglobulinaemia
7/177 patients (4%) had IgG <3 g/L for at least three
consecutive months during follow-up. The median age
at first rituximab dose was 46 years (16–54), diagnoses
were primary systemic vasculitis (N = 5), and SLE (N = 2).
Median disease duration before rituximab was 57 months
(8–360). The median number of immunosuppressive
or immunomodulatory agents received excluding
Table 2 Frequency and severity of low immunoglobulin levels
IgG IgM
<0.4 g/L
IgA
<0.8 g/L< 6 g/L Mild Moderate Severe
5-5.9 g/L 3-4.9 g/L < 3 g/L
Baseline hypogammaglobulinaemia 18 (13%) 6 (5%) 9 (6%) 3 (2%) 14 (10%) 14 (10%)
Hypogammaglobulinaemia 61 (34%) 18 (10%) 36 (20%) 7 (4%) 90 (51%) 40 (23%)
Baseline hypogammaglobulinaemia (N = 136): total number and proportion in parentheses of patients with low immunoglobulin levels at time of first rituximab.
Hypogammaglobulinaemia (N = 177): total number and proportion in parentheses of patients with low immunoglobulin levels following rituximab for at least
three consecutive months at some point during follow-up.
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mide in 5/7 patients (71%). Median rituximab exposure
was 5.6 g (2–7.9). Two required intravenous immuno-
globulin (IVIg) as replacement, 9 and 37 months after ri-
tuximab, due to recurrent infections. Four had IgG <3 g/L
during the first six months, 3/4 (75%) had proteinuria
≥3 g/day with IgG levels rising with better disease control.Adverse events
Severe infections
One hundred and seventy severe infections occurred in
71/177 patients (40%) during 8012 patient-months. An-
nual incidence rates of infection were 21.5 cases per 100
patient years in year 1; 10.9 in year 2; 5.2 in year 3; 1.9 in
year 4 and 2.5 in year 5. The time to first severe infection
was not different according to IgG levels (Figure 2).Figure 1 The effect of rituximab on median immunoglobulin levels. M
and interquartile ranges as dashed lines, according to time after first rituxim
177 patients. B. Comparison of IgG levels for all patients with those patient
levels for patients who received <6 g of rituximab in total (N = 79) and pat
levels for patients with (N = 71) and without (N = 106) severe infection.Ninety (53%) were chest infections, 26 (15%) urinary
tract infections, 12 (7%) diarrhoeal illnesses (stool cul-
ture positive), seven (4%) skin infections and 35 (21%)
other infections. Seven opportunistic infections were re-
ported in six patients; three, with granulomatosis with
polyangiitis and severe cavitating lung disease had pul-
monary aspergillosis (one with chronic aspergillosis di-
agnosed before rituximab); 2/3 patients had moderate
hypogammaglobulinaemia including the patient with
chronic aspergillosis who required IVIg replacement;
two had infection with herpes zoster, one with moderate
hypogammaglobulinaemia; and one without hypogam-
maglobulinaemia had both reactivation of Cytomegalo-
virus (CMV) and infection with Mycobacterium avian
intracellulari. No cases of Hepatitis B reactivation or
progressive multifocal leukoencephalopathy (PML) were
reported.edian immunoglobulin levels are represented as a continuous line
ab treatment, from 0 to 60 months. A. IgG, IgM and IgA levels for all
s with IgG <6 g/L before first rituximab (N = 18). C. Comparison of IgG
ients who received ≥6 g of rituximab (N = 98). D. Comparison of IgG
Figure 2 Time to first severe infection following first rituximab.
Time to first severe infection according to IgG levels. The time to first
severe infection was not different when patients with IgG levels ≥6 g/L
(N = 116) and IgG levels <6 g/L (N = 61) (p = 0.953) were compared.
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(42%) with IgG <6 g/L experienced severe infections
(p = 0.750) (Table 3). 43 severe infections occurred in
17/36 patients (47%) with moderate and eight in 2/7
patients (29%) with severe hypogammaglobulinaemia.
There were no differences in median overall IgG levels
between patients with and without infection (Figure 1D).
Fourteen severe infections occurred in 7/18 (39%) with
baseline IgG <6 g/L and 95 occurred in 44/118 (37%) with
baseline IgG ≥6 g/L (p = 1.00). There was no difference in
the proportion of patients affected by infection according
IgM and IgA levels (Table 3).
There was a positive correlation (r = 0.265, (CI 0.118
to 0.401) (p < 0.001)) between cumulative oral prednis-
olone exposure and the occurrence of infection. How-
ever, no correlation was seen between risk of infection
and cumulative rituximab exposure (r = −0.093 (CI −0.242
to −0.060) (p = 0.217) or prior cumulative cyclophospha-
mide exposure (r = 0.084 (CI −0.072 to 0.235) (p = 0.276).
Need for IVIg
6/177 patients (3%) received IVIg as replacement. Median
age at first rituximab was 43 years (16–67); medianTable 3 Severe infections according to immunoglobulin
subtype and levels
Normal immunoglobulin
levels
Low immunoglobulin
levels
IgG ≥6 g/L <6 g/L
Patients affected 45/115 (39%) 26/62 (42%)
IgM ≥0.4 g/L <0.4 g/L
Patients affected 32/87 (37%) 39/90 (43%)
IgA ≥0.8 g/L <0.8 g/L
Patients affected 56/137 (41%) 15/40 (38%)
The number and proportion of patients suffering severe infections according
immunoglobulin subtype (IgG, IgM and IgA) and immunoglobulin level are
presented. There is no difference in the proportion of patients affected by infection
when comparing IgG levels ≥6 g/L and <6 g/L (p = 0.750); IgM levels ≥0.4 g/L
and <0.4 g/L (p = 0.6) and IgA levels ≥0.8 g/L and <0.8 g/L (p = 0.855).rituximab exposure was 5.9 g (4–11.1). The median time
from first rituximab treatment to start of replacement was
18.5 months [4-37]. The median IgG level before first ri-
tuximab was 4.8 g/L (4.4-5.8) and IgG level before first
IVIg was 3.9 g/L (3.1-4.8). All patients had recurrent infec-
tions despite antibiotic prophylaxis and 5/6 had chronic
lung disease.
Deaths
Thirteen patients (4 SLE, 6 primary systemic vasculitis,
3 other autoimmune diseases) died. The median age at
first rituximab treatment was 62 years (43–82). Causes
of death were: respiratory failure (n = 2 at 10 and
28 months after first rituximab) both with pre-existing
pulmonary fibrosis; infection (n = 4 at 4, 15, 49 and
84 months) one with peritonitis, two with sepsis and ac-
tive SLE with chronic kidney disease, and one with chest
sepsis with chronic kidney disease and ischemic heart
disease; myocardial infarction (n = 1, at 47 months), ma-
lignancy (n = 2 at 27 and 31 months); unknown cause
(n = 4 at 2, 3, 5 and 16 months). 2/13 patients (15%) had
mild hypogammaglobulinaemia and 3/13 (23%) moder-
ate hypogammaglobulinaemia.
Discussion
Rituximab is an effective therapy for remission induction in
patients with multi-system autoimmune disease [1,2,26,29].
However, the majority of patients will relapse after a single
course [3,5]. Further courses are effective, although con-
cerns surround the long term effect on humoral immunity
and infection risk with repeated rituximab use [30,31]. Ri-
tuximab depletes CD20+ B cells for an average of 6–12
months. Mature plasma cells (the source of 95% of circulat-
ing IgG) do not express CD20; however, prolonged deple-
tion of plasma cell precursors may reduce replenishment
of mature plasma cells leading to hypogammaglobulinae-
mia and infection risk.
We studied the frequency and severity of hypogam-
maglobulinaemia and severe infections following re-
peated rituximab dosing in patients with multi-system
autoimmune disease. Low IgG, IgM and IgA levels were
more frequent before first rituximab (13%, 10% and 10%
of patients respectively) than in NHL or RA [16,17,32-34].
At 60 months, the proportion of patients with low IgG
remained stable (14%) however, those with low IgM or IgA
rose to 25% (p = 0.018) and 17% (p = 0.211) respectively.
The increase in proportion of patients with IgM <0.4 g/L
following rituximab, is consistent with previous data in
SLE and AAV patients [3,20-23,26]. Low levels of IgG,
IgM and IgA occurred in 34%, 51% and 23% of patients
for at least 3 consecutive months at any time during
follow-up. In keeping with the overall stabile proportion
of patients with low IgG during follow-up, the majority
of episodes of IgG hypogammaglobulinaemia were mild or
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prolonged IgG hypogammaglobulinaemia. IgG levels were
lower at baseline in patients who had received prior cyclo-
phosphamide treatment. However, the development of
IgG hypogammaglobulinaemia was not associated with
prior cyclophosphamide exposure, but was associated
with a higher cumulative corticosteroid exposure during
follow-up. Median IgG levels trended downwards in
those who received >6 g rituximab, although this did
not reach statistical significance.
Our study is retrospective and whilst it does represent
real life event rates of hypogammaglobulinaemia and se-
vere infections, in patients with complex multisystem
autoimmune disease treated with rituximab, outcomes
are confounded by clinical strategies to reduce infection
risk, and concomitant therapies that contribute to hypo-
gammaglobulinaemia and infection risk. In our practice
repeat rituximab dosing is used to treat and prevent dis-
ease flare irrespective of peripheral blood B cell count.
Immunoglobulins are monitored at each clinic visit.
Concomitant immunosuppressive therapies are generally
not used alongside rituximab and during follow-up cor-
ticosteroids are reduced or withdrawn. In patients with
repeated infections, antibiotic prophylaxis is employed;
and in patients with infections despite antibiotics and
moderate/severe hypogammaglobulinaemia (IgG < 5 g/l),
IVIG replacement is used. Discontinuation of further ri-
tuximab dosing is considered in patients with IgG < 5 g/l
with a downward (rather than stable) trajectory and re-
current infections; however, this decision is balanced
against ongoing disease activity, the efficacy benefit
derived from rituximab and the availability of other
therapeutic options.
Existing data supports the safety of repeated doses of
rituximab in RA and NHL, where stable infection rates
were observed following initiation of rituximab treatment
[33,35,36]. We observed infections in 38% of patients in
the first year of treatment; similar to rates seen in other
studies in primary systemic vasculitis [1,2,37,38] where
active disease, chronic lung and kidney disease, prior
cyclophosphamide and high corticosteroid exposure
also contribute to infection risk. As in RA and NHL, the
occurrence of persistent mild hypogammaglobulinaemia
(IgG 5–6 g/l) following rituximab was not associated
with a higher infection rate [33,35,36]. Unlike other
populations, where IgG levels <5 g/l have been associated
with infection risk [34], we did not observe an association;
however, regular monitoring, antibiotic prophylaxis and
IVIG replacement may have reduced infection rates in this
subgroup.
Overall we observed a reduction in severe infection rates
over time, along with improved disease control, a minimisa-
tion of corticosteroids and avoidance of concomitant im-
munosuppression. Our data suggest that provided carefulmonitoring is employed together with judicious use of
prophylactic therapies, the IgM hypogammaglobulinaemia,
transient mild/moderate IgG hypogammaglobulinaemia or
occasional severe IgG hypogammaglobulinaemia observed
with repeat rituximab dosing are not dominant factors in
infection risk in a severe multisystem autoimmune dis-
ease population.
Conclusion
We have reported on the frequency and severity of hy-
pogammaglobulinaemia and potential infective complica-
tions following rituximab therapy in a large retrospective
survey of patients with multi-system autoimmune disease
with long term follow-up. Following rituximab treatment
the proportion of patients with IgM and IgA hypogamma-
globulinaemia rose, but the proportion with IgG hypo-
gammaglobulinaemia remained stable. The risk of IgG
hypogammaglobulinaemia was not increased by low base-
line immunoglobulin levels or prior cyclophosphamide
therapy or greater cumulative rituximab exposure. How-
ever, patients with high concomitant glucocorticoid doses
were at risk of developing IgG hypogammaglobulinaemia.
Only a small minority developed severe IgG hypogam-
maglobulinaemia necessitating IVIG replacement. Severe
infections were frequent in this patient population and
were associated with higher glucocorticoid exposure but
were not associated with IgG levels. Overall, rituximab
was a safe therapy in this population. Regular immuno-
globulin monitoring is indicated with repeat rituximab
dosing to identify the small minority of patients with
progressively falling IgG levels.
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